Beginning as early as April 1, 2026, Medicare beneficiaries will pay no more than $50 per month for Lillys Zepbound (tirzepatide), available in a multi-dose pen, and for orforglipron, Lilly's once-daily obesity pill, provided both receive approval from the US Food and Drug Administration (FDA), according to a news release from Lilly
Some customers praise the quality of packaging, report successful weight loss outcomes (one reviewer noted losing 35 pounds), and express satisfaction with the medication itself
Reported or plausible effects discussed by users and in limited literature include injection-site irritation (if used by injection), headache, nausea, fatigue, lightheadedness, and changes in sleep
For a full plain-language explainer, see our bacteriostatic water research guide
Aslam B, Asghar R, Muzammil S, Shafique M, Siddique AB, Khurshid M, et al
A.WangT